CrossRef Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study X
Articles were excluded if they had irrelevant content, were non-English language text, and were non-case studies
This mechanistic insight positions CPT as a targeted modulator of mitochondrial RET, linking structural complex I regulation to redox homeostasis and neuronal survival, and underscores its therapeutic potential in PD
DOI Dou Y, Lee A, Zhu L, et al
Only medical professionals, doctors, dermatologists, plastic surgeons, and licensed aestheticians can place an order
Tony explains this positioning strategy allows them to target different demographics with the same ingredients, similar to how they might position Setria differently for immune health versus skin health applications